&nbsp;

NDFP & EBP Resubmissions and Appeals Policy

Dec 2017

Regimen

NELA

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative

Drugs Used:

nelarabine (Unfunded)

Quick Link(s):

Regimen Monograph

Feb 2024

Blog posts

New cancer statistics: Better outcomes, but increasing need in Ontario

This year, more than 90,000 people in Ontario will discover they have cancer. Approximately one in two Ontarians are expected to be diagnosed with...

Jan 2018

Regimen

NIVL

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Drugs Used:

nivolumab (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NIVL

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Funding:

New Drug Funding Program

Nivolumab - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma

New Drug Funding Program

Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Oct 2024

Regimen

NIVL(MNT)

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NIVL(MNT)

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Aug 2024

Cancer facts

New cases of intra-oral cancers increasing after decades of decline

Jan 2019

Document

newWindow-icon-LightBlue.png

Jan 2019

Document

newWindowIconLightBlue.png

Jan 2019

Regimen

NIVL(MNT)

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

nivolumab (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2024

Document